

ADHD Therapeutics: Market Research Report

<https://marketpublishers.com/r/AF899B62785EN.html>

Date: June 2010

Pages: 321

Price: US\$ 3,950.00 (Single User License)

ID: AF899B62785EN

Abstracts

This report analyzes the worldwide markets for ADHD Therapeutics in US\$ Million.

The report provides separate comprehensive analytics for the US and Rest of World.

Annual estimates and forecasts are provided for each region for the period of 2006 through 2015.

The report profiles 27 companies including many key and niche players such as Eli Lilly & Company, Johnson & Johnson, Janssen-Cilag, Novartis AG, Shire Plc, UCB S.A., Companies with Drugs in Pipeline for ADHD: Abbott Laboratories, Inc., Cortex Pharmaceuticals, Inc., KemPharm, Inc., and NeuroSearch A/S.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

A Prelude
Lack of Awareness – A Major Impediment
Adult ADHD – A Growing Market Opportunity

Table 1. Market Share of ADHD Prescriptions by Age Category: Children, Adolescents and Adults (includes corresponding Graph/Chart)

Unfulfilled Needs Provide Impetus to Develop New Molecules
Safety Concerns Foster Research in Non Stimulant Segment
Presence of Co-morbidities with ADHD Creates Opportunities for Combination Therapies
Introduction of Generics Shakes Market
Patent Expiries of Major Drugs in the ADHD Market

2. COMPETITIVE SCENARIO

Table 2. Leading Brands in the Global ADHD Market by Prescription Share (2008) (includes corresponding Graph/Chart)

Shire Leads the Way
J&J's Concerta – Leading Drug for ADHD by Default
Eli Lilly's Strattera – Creating a Niche
Novartis Retains Market Share

Pipeline Drugs

3.THE ADHD CONUNDRUM

ADHD – A Disorder or Marketing Gimmick of Pharmaceutical Companies?

Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market

Differences in Diagnostic Criteria in Europe and US

Hiccups in the Way

ADHD in Women

4.ADHD – AN INSIGHT

Attention Deficit Hyperactivity Disorder (ADHD) – Introduction

Brief History of the Disorder

Common Co-Occurring Disorders With ADHD

Consequences of ADHD

What Leads to ADHD?

Study Reveals Deficits in Protein Levels in Brain's Reward/Motivation System

ADHD Symptoms

DSM IV Criteria for Diagnosis of ADHD

DSM IV Criteria for Inattention and Hyperactivity/ Impulsivity

Types of ADHD

Treating ADHD

Stimulants

Non-stimulants

Others

5.REVIEW OF SELECT DRUGS

ADHD Drugs – Background

Brand Review

Ritalin LA

Focalin

Table 3. Global Revenues of Novartis' ADHD Drugs - Ritalin/Focalin (2008-2009) (in US\$ million)

Concerta

Table 4. Global Revenues of Concerta (2006-2009) (includes corresponding Graph/Chart)

Strattera

Table 5. Global Revenues of Strattera (2006-2009) (in US\$ million) (includes corresponding Graph/Chart)

Metadate CD

Table 6. Global Revenues of Metadate CD/Equasym (2007-2008) (in €Million)

Adderall XR

Table 7. Global Revenues of Adderall XR (2006-2009) (in US\$ million) (includes corresponding Graph/Chart)

Daytrana

Table 8. Global Revenues of Daytrana (2006-2009) (in US\$ million) (includes corresponding Graph/Chart)

Vyvanse

Table 9. Global Revenues of Vyvanse (2007-2009) (in US\$ million) (includes corresponding Graph/Chart)

Intuniv

6.RESEARCH PIPELINE

Supernus Pharmaceuticals' SPN 810 Proves Successful in Phase IIa Clinical Trials

KemPharm Announces Completion of Phase I Trials of KP106
Shire Announces Results of Phase IIIb Clinical Trials of Daytrana® in Adolescents
Addrenex and Sciele Pharma Submit sNDA for Clonicef for ADHD Treatment
Targacept Collaborates with AstraZeneca for AZD3480 Clinical Trials
Neptune Technologies Announces Positive Reports on Pre-Clinical Trials of Medical Food Candidate for Treatment of ADHD
NeuroSearch Completes Phase II Studies on Efficacy and Security of ABT-894 in Adults with ADHD
Abbott Announces Positive Results From Phase II Studies of a Novel Approach of Treating ADHD

7.PRODUCT LAUNCHES/INTRODUCTIONS

Shire Unveils First Prodrug Therapy for ADHD in Canadian Market
Teva Launches First Authorized Generic Version of Adderall XR® Capsules
Shire Introduces INTUNIV™
Eli Lilly Japan Introduces Strattera in the Country

8.RECENT INDUSTRY ACTIVITY

Avacta Group Acquires TheraGenetics
AstraZeneca Grants Interim Payment to Targacept
Addrenex Pharmaceuticals Inks Agreement with Dream Pharma
Durect Signs Agreement with Orient Pharma
Hisamitsu Pharmaceutical Acquires Noven Pharmaceutical
Shire Receives FDA Approval for INTUNIV Tablets
Shire Pharmaceuticals and GSK Sign a Co-Promotion Deal for Vyvanse
Shire Pharmaceuticals Establishes Office in Tokyo
Shire and UCB Enter into Agreement
Shire Retains Exclusivity for Vyvanse
Shire Settles Litigation with Sandoz for Generic Adderall
Sciele Pharma to Takeover Addrenex Pharmaceuticals
Auriga Laboratories Receives Approval from FDA for Liquadd™
Concerta Extended Release Tablets Receive US FDA Approval for Use in Adult Treatment
Eurand Enters into Settlement with UCB
Paladin Labs Secures Dexedrine's Distribution Rights from GlaxoSmithKline
Shire Receives Approval from FDA for Use of Vyvanse in Adults
Strattera Receives FDA Approval for Maintenance of ADHD in Children & Adolescents

The Dore Group Providing Alternate ADHD Treatment to Drugs Goes Into Liquidation
Shire Takes Over New River Pharmaceuticals to Gain Full Control Over Vyvanse™

9.FOCUS ON SELECT PLAYERS

Eli Lilly & Company (USA)
Johnson & Johnson (USA)
Janssen-Cilag (Switzerland)
Novartis AG (Switzerland)
Shire Plc (The UK)
UCB S.A. (Belgium)
Companies with Drugs in Pipeline for ADHD
Abbott Laboratories, Inc. (USA)
Cortex Pharmaceuticals, Inc. (US)
KemPharm, Inc. (USA)
NeuroSearch A/S (Denmark)

10.GLOBAL MARKET PERSPECTIVE

Table 10. World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 11. World 10 -Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Market by Geographic Region – Percentage Breakdown of Revenues for US and Rest of World Markets for Years 2006, 2009 and 2015

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Current and Future Analysis
ADHD Epidemic in the US !

Table 12. Prevalence Rate of ADHD in Different Backgrounds According to Age, Ethnicity, Gender and Family Structure in the US in 2007

Causes for Widespread ADHD Diagnosis and Treatment in the US
ADHD Drugs Combat Safety Concerns
Market Exhibits Greater Potential

Table 13. Percentage Share of ADHD Prescriptions in US by Patient Category - Children, Adolescents and Adults (2002 and 2007) (includes corresponding Graph/Chart)

Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
Cyclical Nature of ADHD Market
Competitive Scenario

Table 14. Leading Players and Drug Brands in the US ADHD Market (2007, 2008) : Percentage Breakdown of Prescriptions for Shire, McNeil Janssen, Eli Lilly, Novartis, Celltech, Pharmaceuticals / UCB, and Others (includes corresponding Graph/Chart)

Product Launches
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 15. US Recent Past, Current & Future Analysis for Sales Force Automation (SFA) Market Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2.REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis
Review of Select Markets
Canada

Concerta Leads the Market

Table 16. Leading Drug Brands in the Canadian ADHD Market (2008): Percentage Share Breakdown of Revenues for Concerta, Adderall, Dexedrine, Generics, and Others (includes corresponding Graph/Chart)

Europe
Germany

Table 17. Prevalence Rates of ADHD in Germany in Terms of Gender, Age and Socioeconomic Status Reimbursement Policy

The United Kingdom
Australia
Product Launches
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 18. Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Drugs Analyzed with Annual Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 27 (including Divisions/Subsidiaries - 33)

Region/Country Players

The United States

Japan

Europe

Germany

The United Kingdom

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

I would like to order

Product name: ADHD Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/AF899B62785EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF899B62785EN.html>